Table 1.
Comparative efficacy of targeted therapies for overall response rate in the network meta-analysis based on the Bayesian approach.
| Afat | 0.95 (0.38–2.31) | 2.22 (1.25–3.98) | 0.34 (0.01–3.81) | 0.71 (0.28–1.73) | 2.46 (1.25–4.90) | 2.63 (1.56–4.50) | 1.18 (0.55–2.46) | 3.53 (2.06–6.15) | 2.64 (1.54–4.58) | 2.08 (1.18–3.68) | 1.18 (0.39–3.51) | 2.11 (1.00–4.49) | 2.03 (1.07–3.88) |
| 1.06 (0.43–2.62) | Alec | 2.34 (1.08–5.22) | 0.36 (0.01–4.26) | 0.74 (0.26–2.10) | 2.60 (1.10–6.27) | 2.78 (1.36–5.80) | 1.24 (0.67–2.27) | 3.74 (1.75–8.22) | 2.79 (1.32–6.02) | 2.20 (1.03–4.78) | 1.24 (0.37–4.21) | 2.24 (0.90–5.71) | 2.15 (0.93–5.03) |
| 0.45 (0.25–0.80) | 0.42 (0.19–0.93) | Beva | 0.15 (0.01–1.63) | 0.31 (0.14–0.70) | 1.11 (0.70–1.78) | 1.19 (0.87–1.62) | 0.52 (0.28–0.96) | 1.59 (1.25–2.05) | 1.19 (0.87–1.63) | 0.94 (0.66–1.32) | 0.53 (0.19–1.46) | 0.95 (0.54–1.69) | 0.92 (0.59–1.41) |
| 2.93 (0.26–78.11) | 2.79 (0.23–76.6) | 6.49 (0.62–170) | Cabo | 2.08 (0.17–57.3) | 7.21 (0.67–193) | 7.72 (0.74–202) | 3.45 (0.30–92.0) | 10.36 (0.99–272) | 7.74 (0.75–201) | 6.09 (0.58–162) | 3.45 (0.27–104) | 6.20 (0.56–166) | 5.95 (0.56–157) |
| 1.43 (0.58–3.57) | 1.35 (0.48–3.78) | 3.16 (1.43–7.12) | 0.49 (0.02–5.78) | Ceri | 3.51 (1.45–8.60) | 3.75 (1.80–7.94) | 1.66 (0.68–4.13) | 5.04 (2.30–11.2) | 3.76 (1.74–8.25) | 2.96 (1.36–6.54) | 1.68 (0.50–5.65) | 3.02 (1.18–7.83) | 2.89 (1.23–6.89) |
| 0.41 (0.20–0.80) | 0.38 (0.16–0.91) | 0.90 (0.56–1.44) | 0.14 (0.01–1.49) | 0.28 (0.12–0.69) | Cetu | 1.07 (0.65–1.73) | 0.47 (0.23–0.96) | 1.44 (0.96–2.14) | 1.07 (0.67–1.72) | 0.84 (0.51–1.38) | 0.48 (0.16–1.41) | 0.86 (0.45–1.65) | 0.82 (0.48–1.41) |
| 0.38 (0.22–0.64) | 0.36 (0.17–0.74) | 0.84 (0.62–1.15) | 0.13 (0.00–1.35) | 0.27 (0.13–0.56) | 0.93 (0.58–1.53) | Chem | 0.44 (0.26–0.75) | 1.34 (1.03–1.77) | 1.00 (0.80–1.25) | 0.79 (0.61–1.02) | 0.45 (0.17–1.17) | 0.80 (0.45–1.45) | 0.77 (0.50–1.19) |
| 0.86 (0.41–1.82) | 0.81 (0.44–1.49) | 1.90 (1.04–3.51) | 0.29 (0.01–3.28) | 0.60 (0.24–1.48) | 2.11 (1.04–4.34) | 2.26 (1.34–3.82) | Criz | 3.03 (1.69–5.50) | 2.26 (1.29–4.03) | 1.78 (0.99–3.20) | 1.01 (0.34–3.03) | 1.81 (0.84–3.99) | 1.74 (0.89–3.45) |
| 0.28 (0.16–0.49) | 0.26 (0.12–0.57) | 0.63 (0.49–0.80) | 0.10 (0.00–1.01) | 0.20 (0.09–0.43) | 0.70 (0.47–1.04) | 0.75 (0.57–0.98) | 0.33 (0.18–0.59) | Dum | 0.75 (0.58–0.96) | 0.59 (0.44–0.78) | 0.33 (0.12–0.91) | 0.60 (0.36–1.00) | 0.57 (0.40–0.82) |
| 0.38 (0.22–0.65) | 0.36 (0.17–0.76) | 0.84 (0.61–1.15) | 0.13 (0.00–1.33) | 0.26 (0.12–0.57) | 0.93 (0.58–1.50) | 1.00 (0.80–1.24) | 0.44 (0.25–0.78) | 1.34 (1.05–1.72) | Erlo | 0.79 (0.59–1.04) | 0.45 (0.16–1.19) | 0.80 (0.46–1.42) | 0.77 (0.51–1.16) |
| 0.48 (0.27–0.85) | 0.45 (0.21–0.98) | 1.07 (0.76–1.51) | 0.16 (0.01–1.72) | 0.34 (0.15–0.74) | 1.19 (0.73–1.94) | 1.27 (0.98–1.63) | 0.56 (0.31–1.01) | 1.70 (1.28–2.27) | 1.27 (0.96–1.68) | Gefi | 0.57 (0.21–1.53) | 1.02 (0.57–1.83) | 0.98 (0.63–1.51) |
| 0.85 (0.29–2.56) | 0.80 (0.24–2.70) | 1.88 (0.68–5.22) | 0.29 (0.01–3.75) | 0.59 (0.18–2.01) | 2.09 (0.71–6.26) | 2.24 (0.85–5.94) | 0.99 (0.33–2.97) | 3.01 (1.10–8.30) | 2.24 (0.84–6.07) | 1.77 (0.65–4.84) | Osim | 1.80 (0.59–5.63) | 1.73 (0.60–5.02) |
| 0.47 (0.22–1.00) | 0.44 (0.18–1.12) | 1.05 (0.59–1.85) | 0.16 (0.01–1.79) | 0.33 (0.13–0.84) | 1.16 (0.61–2.23) | 1.25 (0.69–2.22) | 0.55 (0.25–1.19) | 1.67 (1.00–2.78) | 1.25 (0.71–2.20) | 0.98 (0.55–1.76) | 0.56 (0.18–1.70) | Ramu | 0.96 (0.51–1.79) |
| 0.49 (0.26–0.94) | 0.46 (0.20–1.07) | 1.09 (0.71–1.69) | 0.17 (0.01–1.77) | 0.34 (0.15–0.81) | 1.21 (0.71–2.09) | 1.30 (0.84–2.00) | 0.57 (0.29–1.13) | 1.74 (1.22–2.51) | 1.30 (0.86–1.97) | 1.02 (0.66–1.59) | 0.58 (0.20–1.67) | 1.04 (0.56–1.96) | Vand |
Drugs are reported in alphabetical order. Data in the right-upper triangle are RRs (95% confidence interval, CI) in the row-defining treatment compared with the column-defining treatment. RRs higher than 1 favor the row-defining treatment (the first drug in alphabetical order). RRs for the opposite comparison of ORR are in the left-lower triangle. Each comparison is shown twice in the table, once with drug A vs. drug B and once with drug B vs. drug A. Significant results are in italic and underscored. RR, response ratio; CI, confidence interval; ORR: overall response rate; Afat, afatinib; Alec, alectinib; Beva, bevacizumab; Cabo, cabozantinib; Ceri, ceritinib; Cetu, cetuximab; Chem, chemotherapy; Criz, crizotinib; Dum, dummy; Erlo, erlotinib; Gefi, gefitinib; Osim, osimertinib; Ramu, ramucirumab; Vand, vandetanib.